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Genome-wide DNA methylation analysis of human brain
tissue from schizophrenia patients
LF Wockner1, EP Noble2, BR Lawford3,4, RMcD Young3, CP Morris3, VLJ Whitehall1 and J Voisey3
Recent studies suggest that genetic and environmental factors do not account for all the schizophrenia risk, and epigenetics also
has a role in disease susceptibility. DNA methylation is a heritable epigenetic modification that can regulate gene expression.
Genome-wide DNA methylation analysis was performed on post-mortem human brain tissue from 24 patients with schizophrenia
and 24 unaffected controls. DNA methylation was assessed at over 485 000 CpG sites using the Illumina Infinium
HumanMethylation450 Bead Chip. After adjusting for age and post-mortem interval, 4641 probes corresponding to 2929 unique
genes were found to be differentially methylated. Of those genes, 1291 were located in a CpG island and 817 were in a promoter
region. These include NOS1, AKT1, DTNBP1, DNMT1, PPP3CC and SOX10, which have previously been associated with schizophrenia.
More than 100 of these genes overlap with a previous DNA methylation study of peripheral blood from schizophrenia patients in
which 27 000 CpG sites were analysed. Unsupervised clustering analysis of the top 3000 most variable probes revealed two distinct
groups with significantly more people with schizophrenia in cluster one compared with controls (P= 1.74 × 10− 4). The first cluster
composed of 88% of patients with schizophrenia and only 12% controls, whereas the second cluster composed of 27% of patients
with schizophrenia and 73% controls. These results strongly suggest that differential DNA methylation is important in schizophrenia
etiology and add support for the use of DNA methylation profiles as a future prognostic indicator of schizophrenia.
Translational Psychiatry (2014) 4, e339; doi:10.1038/tp.2013.111; published online 7 January 2014
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INTRODUCTION
Despite schizophrenia being a debilitating disorder affecting 1%
of the population, there are no extant biomarkers to aid the
clinician in identifying this disorder. Studies predict the genetic
risk to be up to 80%,1,2 but despite strenuous research efforts the
genes and polymorphisms found to be associated with schizo-
phrenia account for very little of the genetic risk. Environmental
risk such as urbancity,3 migrant status,4 childhood maltreatment,5
prenatal infections,6 cannabis use7 and maternal vitamin D
deficiency8 also contribute to schizophrenia susceptibility. How-
ever, not all individuals exposed to environmental risk develop
schizophrenia.9 This observation suggests that interaction
between susceptibility genes and environmental factors may
better account for schizophrenia. DNA methylation has been
identified as a key mechanism for environmental regulation of
gene expression.10 DNA methylation is an epigenetic modification
that is essential for normal human development via regulation of
gene function. DNA methylation results in the addition of a methyl
group on the cytosine of CpG dinucleotides, which can then be
inherited through cell division. These cytosine modifications can
affect gene expression by altering the binding of transcription
factors to promoter regions or changing mRNA processing.
DNA methylation studies of the brain and peripheral tissue have
previously been reported for schizophrenia. However, to our
knowledge, no study has published results from an Illumina
Infinium HumanMethylation450 Beadchip in the brain tissue of
patients with schizophrenia. Studies to date have typically been
performed in peripheral tissues and have been limited to the
analysis of CpG islands in the promoter regions. A recent DNA
methylation study analysed 27 578 CpG sites in peripheral blood
cells from 18 patients with schizophrenia and 15 normal
controls.11 This study revealed 603 CpG sites (representing 589
genes) that had significantly different DNA methylation levels
between schizophrenia and controls. Among these genes were
HTR1E, COMTD1 and SLC6A3, which have previously been found to
be associated with schizophrenia. An epigenetic study of
monozygotic twins discordant for schizophrenia identified a
number of loci differentially methylated in peripheral blood.12
Selected gene promoters have also been analysed for differential
DNA methylation in the brain tissue from small numbers of
patients with schizophrenia. Some of these genes include
RELN,13,14 COMT,15 SOX1016 and HTR2A.17 An earlier study of 12
000 CpG islands in the frontal cortex of 35 schizophrenia and 35
controls revealed differential DNA methylation in genes associated
with glutamatergic and GABAergic pathways.18 Apart from the
present study, the only extant study using a 450 000 genome-wide
methylation array was performed in leukocytes from patients with
schizophrenia.19
DNA methylation analysis of schizophrenia has been more
widely performed in peripheral tissue, because it can be readily
obtained from living patients. The epigenetic profile differs in the
brain compared with the peripheral tissue; however, some regions
may have common patterns,20 which would make these regions
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ideal as potential biomarkers for schizophrenia. Some of the genes
found to be differentially methylated in peripheral tissue of
schizophrenia patients include HTR1A,21 HTR2A,22BDNF,23 GRM2,24
GRM524 and COMT.25,26
Brain tissue from the Human Brain and Spinal Fluid Resource
Centre, CA, USA, was obtained in order to examine tissue involved
in the etiology of schizophrenia. We analysed this tissue in a
genome-wide methylation study of schizophrenia. We report
significant differences in methylation status in brain tissue from
schizophrenia patients compared with that from controls. In
addition, unsupervised clustering analysis revealed two distinct
groups corresponding to schizophrenia and controls. Results of
future epigenetic studies hold great promise of a schizophrenia
biomarker and treatment, as epigenetic processes can be
reversed.
MATERIALS AND METHODS
Samples
Frontal cortex post-mortem brain tissue from individuals with Diagnostic
and Statistical Manual of Mental Disorders, 4th Edition-diagnosed
schizophrenia (n= 24) and controls (n= 24) was provided by the Human
Brain and Spinal Fluid Resource Centre (courtesy of James Riehl). Each
sample consisted of a coronal section (7-mm thick) that had been quick
frozen, and a section of frontal cortex was dissected from each frozen
section sample weighing (0.4–1.0 g). Demographic data, including age,
post-mortem interval (PMI) and gender, are summarised in Table 1. PMI in
our study is defined as the time between death and when the brain
section is quick frozen. The mean (± s.d.) time between death and the
tissue stored at 4 °C was 4.48±3.86. All but two of the schizophrenia
subjects were known to be receiving antipsychotic medication at time of
death. Cause of death of five schizophrenia patients was suicide. Extraction
of DNA was performed at the UCLA Clinical Microarray Core Laboratory
(Los Angeles, CA, USA) using the Roche MagNa Pure Compact (Roche, CA,
USA). The quality and quantity of DNA was assessed using spectro-
photometry, and was found to be satisfactory for all samples. Ethics
approval for the project was obtained from the Human Research Ethics
Committee of the Queensland University of Technology.
Illumina Infinium HumanMethylation450 Beadchip
DNA samples were sent to the Australian Genome Research Facility and
stored at −20 °C. Quality checking of the samples was performed by
Nanodrop Spectrophotometer (Nanodrop, Wilmington, DE, USA) and
resolution on a 0.8% agarose gel. Samples were bisulphite converted with
Zymo EZ DNA Methylation kit (Zymo Research, Irvine, CA, USA).
GenomeStudio v2011.1 (Illumina, San Diego, CA, USA) with Methylation
module 1.9.0 software with the default Illumina settings and Illumina
HumanMethylation450_15017482_v.1.2 manifest files was used in the
methylation analysis. The Infinium platform assays more than 485 000 CpG
sites, encompassing 99% of RefSeq genes. It covers 96% of CpG islands
with multiple sites in the island, the shores (within 2 kb from CpG islands)
and the shelves (>2 kb from CpG islands). It also covers CpG sites outside of
CpG islands and DNase hypersensitive sites, as well as incorporating
miRNA promoter regions. All the Illumina quality controls were found to be
in order, which included sample-independent controls, sample-dependent
controls, staining controls, extension controls, target removal controls,
hybridization controls, bisulphite conversion I and II controls, specificity
controls, non-polymorphic controls and negative controls.
Data processing
For methylation analysis, IDAT files were loaded into the R (2.15)
environment using the Bioconductor minfi package (1.4.0).27 The arrays
were then background and control normalised using the minfi package.
Technical differences between Infinium I and Infinium II probes were
removed using Subset-quantile Within-Array Normalisation, developed by
Maksimovic et al.28 and available in the minfi package. The methylation
status for each probe was recorded as a β-value that ranged between 0
and 1, where values close to 1 represent high levels of methylation and
where values close to 0 represent low levels of methylation.
A detection P-value was calculated for all probes on all arrays. A P-
value>0.05 indicates that the data point is not significantly different from
background measurements. Probes were removed from analysis if >50% of
the samples had a detection P-value>0.05 (n=39).
Next, probes that are designed for sequences on either the X (n=11
232) or Y (n= 416) chromosome were removed. Finally, probes with single-
nucleotide polymorphisms present within 10–50 bp from query site (n=59
892), and within o10 bp from query site (n= 36 535) were removed; with
overlap, this totalled n=89 678 probes. Because of overlap in some of
these conditions, n= 100 345 probes were filtered leaving n= 385 167 for
analysis.
Differential methylation detection
In order to assess differences in methylation between groups, the original
n= 385 167 β-values were converted to M-values via the logit transforma-
tion as recommended by Du et al.29 Differentially methylated probes were
detected using the limma package.30 The limma procedure uses linear
models to assess differential methylation, whereby information is shared
across probes.31 A major benefit of the limma procedure is that it allows
the inclusion of covariates (such as age) or other factors (such as PMI) in
the specification of the linear model. As such, we were able to adjust for
age and PMI in the detection of differentially methylated probes by
including age and autolysis covariates in the specification of the design
matrix. Although most studies have found that methylation status is
unaffected by PMI, we decided to adjust for PMI as a confounder.32,33
Probes were considered to be differentially methylated if the resulting
adjusted P-value was o0.05. The Benjamini–Hochberg method34 was
used to adjust the P-values and ensure that the false discovery rate was
o0.05. The corresponding gene list was derived from the gene
annotations associated with the probes.
Unsupervised clustering
For cluster analysis, the top 3000 most variable probes were selected
(based on the s.d. of the β-value). A recursively partitioned mixture model
(RPMM) was used to cluster the β-scores. RPMM is a model-based
unsupervised clustering algorithm developed for measurements that lie
between 0 and 1. This algorithm was implemented using the RPMM
Bioconductor package.35 The implementation of RPMM was identical to
Hinoue et al.36 who used a fuzzy clustering algorithm for initialisation and
level-weighted version of Bayesian Information Criterion as a split criterion.
In order to adjust for age and PMI, a series of linear models were fitted to
the M-values (logit-transformed β-values) using the function lmFit in the
limma package. Coefficients for age and PMI, along with an intercept were
estimated for each probe. Owing to this model specification, the residuals
of the linear model represent the methylation values adjusted for the
effect of age and PMI. The residuals were then back-transformed and
clustered using the RPMM method implemented for the unadjusted
probes.
To allow visualisation of the distance between samples and to further
reinforce the RPMM clustering, multidimensional scaling with a Euclidian
distance metric was performed on both the adjusted M-values (before
back transformation) and the adjusted β-values. The first two coordinates,
along with the RPMM clusters, are visualised in Figures 1a and b.
RESULTS
Differential methylation
Between the 24 controls and the 24 schizophrenia samples, a total
of 19 582 probes were identified as differentially methylated
(Supplementary Table 1). Approximately 55.9% of probes were
hypomethylated in the schizophrenia group. Of those probes,
2536 were in a promoter-associated region (surrounding a gene
Table 1. Demographic data for control and schizophrenia patients
Control (n= 24) Schizophrenia (n= 23)a P-value
Age, mean (s.d.) 71.3 (9.8) 51.6 (21.6) o0.001
PMI, mean (s.d.)b 14.1 (3.3) 23.8 (10.4) o0.001
Sex, male (%) 19 (79) 16 (67) 0.67
aOne patient did not have age, sex or PMI recorded. bPMI (Post Mortem
Interval) is the time between death and brain tissue quick frozen.
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transcription start site) and 1443 were both promoter-associated
and located at a CpG island (Table 2). However, as the ages and
PMI were significantly different between the controls and the
schizophrenia patients, differential methylation analysis was
performed again, this time adjusting for age and PMI. One sample
from a patient with schizophrenia did not have age, sex or PMI
recorded, and hence they were excluded from the adjusted
analysis.
After adjusting for age and PMI, 4641 probes were declared to
be differentially methylated, with ~47.3% hypomethylated in the
schizophrenia group. The 4641 probes corresponded to 2929
unique genes (Supplementary Table). Of those genes, 817 were
promoter-associated and 599 were both promoter-associated and
located at a CpG island. Furthermore, of the 599 genes both
promoter-associated and located at a CpG island, 491 were in
common with the unadjusted results (Table 2).
As expected, altered DNA methylation mostly occurred in the
CpG islands (29% unadjusted, 34% adjusted; Figure 2) The
proportion of probes in a CpG island found differentially
methylated in the adjusted results is significantly higher than
the overall proportion of probes found in CpG islands on the array
as a whole (overall 30.9%; P= 1.23 × 10− 5). Furthermore, a high
percentage of aberrant DNA methylation occurred in promoter-
associated regions, (13.0% unadjusted, 18.2% adjusted; Figure 2).
The proportion in the unadjusted results is significantly smaller
than the proportion of promoter regions found on the arrays as a
whole (overall 20.2%; P= 7.1 × 10− 4).
The adjusted and unadjusted lists have many genes in common
with previously published results. The largest gene list available is
that of Nishioka et al.37 who published a list of 589 unique genes
associated with probes significantly differentially methylated
between people with first-episode schizophrenia and controls.
Of the 589 genes found differentially methylated in the peripheral
blood samples, 99 overlap with the adjusted list. Seven of the 589
genes found by Nishioka et al.11 were found by Reinius et al.38 to
be differentially methylated between leukocyte subtypes, which
would also explain differences in the two lists.
A gene list was generated based on genes previously found to
be associated with schizophrenia from genetic and/or DNA
methylation studies.11,12,19,37 This gene lists includes DRD2,
NOS1, AKT1, HTR2A, SOX10, FOXP2, DTNBP1, NRG1, PPP3CC, BDNF,
ZNF804A, NRGN, DRD4, MGST1, COMTD1 and GABRB2. Genes
identified as differentially methylated after adjustment include
NOS1, AKT1, DNMT1, SOX10, DTNBP1 and PPP3CC, whose distribu-
tions can be seen in Figure 3.
Cluster analysis
Clustering of the unadjusted β-values revealed three distinct
groups, two containing mostly those with schizophrenia (78% and
100%, respectively), whereas the other group contained a mixture
of the two sample types (Table 3).
Clustering of the age and autolysis-adjusted β-values revealed
two distinct groups, one containing mainly schizophrenia patients
(88%), the other containing mainly controls (73%; Table 3). Cluster
1 had significantly more patients with schizophrenia compared
with controls (χ2 = 14.1; df = 1; P= 1.74 × 10− 4). The multidimen-
sional scaling plots on both the adjusted M- and β-values
(Figure 1) further reinforce the distinction between schizophrenia
patients and controls. Interpreting the results from these three
analyses in conjunction, we can be conservatively confident that
at least 12 out of the 24 patients are clearly distinguishable from
controls.
Figure 1. Multidimensional scaling (MDS) plot of the adjusted M-values with recursively partitioned mixture model (RPMM) cluster of adjusted
β-values denoted by black (cluster 1) or grey (cluster 2) (a). MDS plot of the adjusted β-values with RPMM cluster of adjusted β-values denoted
by black (cluster 1) or grey (cluster 2) (b).
Table 2. Number of probes found to be differentially methylated
between control and schizophrenia patients, both unadjusted and
adjusted for age and PMI
Unadjusted Adjusted Commona
Probes Genes Probes Genes
All 19582 7832 4641 2929 2632
Promoter associated 2536 2084 844 817 677
CpG islands 5650 3336 1575 1291 1083
Promoter associated and
islands
1443 1349 572 599 491
Abbreviation: PMI, post-mortem interval. aGenes in common with
unadjusted results.
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Differential methylation between schizophrenia groups
The results of the clustering indicate that the methylation profiles
in those with schizophrenia are a heterogeneous group. There
were some profiles that were consistently deemed distinct from
the controls, whereas there were others that were not found to be
significantly dissimilar. Twelve samples in particular tended to
exhibit the former trait. When comparing these two potential
subgroups of those with schizophrenia, we can see that the two
subgroups exhibit no obvious difference in characteristics
(Table 4). Thus, there is potential for methylation arrays to be
used to detect differences within these two potential subgroups.
Differential methylation analysis between the two schizophre-
nia subgroups indicated that there were 73 222 probes that were
differentially methylated (Table 5). Of those probes, 6681 were
promoter-associated and 2006 were both promoter-associated
and located at a CpG island. After adjusting for age and PM1, 56
001 probes were found to be differentially methylated
(Supplementary Table 3), 4779 being promoter-associated and
1238 both promoter-associated and located at a CpG island. The
abundance of differentially methylated probes suggests signifi-
cant groupings within the schizophrenia methylation profile. By
contrast, a history of completed suicide or the presence of another
psychiatric disorder revealed no significant differences in
methylation.
DISCUSSION
Differential DNA methylation in schizophrenia has been reported
in several studies to date, although most of these studies involve
the use of non-functional tissues such as blood. In this study, we
analysed DNA methylation status in brain tissue, the primary tissue
of pathology in schizophrenia, employing a genome-wide
methylation array with very extensive coverage of the potential
methylation sites in the human genome. After adjusting for age
and PMI, 4641 probes corresponding to 2929 unique genes were
found to be differentially methylated. When we compared the
differentially methylated gene list with past studies using
peripheral leukocyte samples, we found a high concordance rate,
particularly for genes previously found to be associated with
schizophrenia. Of the 589 genes Nishioka et al.11 found to be
differentially methylated in peripheral blood cells from patients
with schizophrenia, we were able to replicate 99 of these in the
Figure 2. Probe relation to CpG island and probes regulatory feature group. Number of probes found in regions of gene associated, non-gene
associated, promoter associated and unclassified, both (a) unadjusted and (b) adjusted for age and post-mortem interval (PMI) (excluding
those with no regulatory feature group information n= 13214 and n= 3002, respectively). Number of probes found in CpG islands, shelves
(north and south) and shores (north and south), including those with no CpG island information (unknown), both (c) unadjusted and (d)
adjusted for age and PMI.
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brain tissue. This shows promise for the use of non-invasive tissue
such as blood or saliva to be used as a future diagnostic indicator
of schizophrenia. We are aware of only one other study that used
the 450 Illumina array in schizophrenia, although peripheral
leukocytes were analysed rather than the brain tissue.19 That study
identified 10 747 differential DNA methylation sites in medication-
free subjects.19 One of the genes they identified was RAI1, which
has altered DNA methylation in the present study as well as an
earlier schizophrenia study using the brain tissue.18 Other genes
found to be differentially methylated in both the leukocyte study
and the present brain tissue study includes HDAC4, GFRA2 and
GDNF. The leukocyte study did not replicate COMTD1 and HTR1A
that were found to be differentially validated from a previous
Figure 3. Box plots of β-values for the control and schizophrenia groups for probes associated with genes of interest. The median β-value is
denoted by the solid middle line (a) ‘cg27026005’ is promoter associated (PA) and located on a CpG island, it is associated with AKT1. (b)
‘cg01749142’ is also PA and located on a shore, it is associated with AKT1. (c) ‘cg21273407’ is located on a CpG island, it is associated with NOS1.
(d) ‘cg23401624’ is located on a CpG island and is PA, it is associated to DNMT1. (e) ‘cg06128182’ is located on a CpG island and is PA, it is
associated to DNMT1. (f) ‘cg06614002’ is located on a shore and is associated with SOX10.
Table 3. Characteristics of those in the RPMM clusters for both unadjusted and adjusted β-values
Unadjusted Adjusted
Clusters (n) 1 (9) 2 (5) 3 (34) 1 (17) 2 (30)
Schizophrenia, n (%) 7 (78) 5 (100) 12 (35) 15 (88) 8 (27)
Males, n (%) 7 (78) 2 (40) 26 (76) 10 (59) 25 (83)
Death by suicide, n (%) 3 (33) 0 (0) 2 (6) 2 (12) 3 (10)
Age, mean (s.d.) 44.8 (19.6) 69.8 (5) 65 (18.2) 59.8 (19.3) 62.7 (19.4)
PMI, mean (s.d.)a 21.6 (8.7) 20.6 (8.7) 17.8 (12.3) 19.9 (9.0) 18.3 (9.2)
Abbreviations: PMI, post-mortem interval; RPMM, recursively partitioned mixture model. aPMI is the time between death and brain tissue quick frozen.
Table 4. Characteristics of those identified as being in schizophrenia
subgroups based on clustering results
Subgroups 1 2
n 12 12a
Males, n (%) 7 (58) 9 (82)
Death by suicide, n (%) 3 (25) 2 (17)
Age, mean (s.d.) 51.4 (20) 51.8 (24.1)
PMI, mean (s.d.) 22 (10.2) 25.7 (10.8)
aOne person in this group did not have sex, age or post-mortem interval
recorded.
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study in the peripheral tissue.11,19 However, we report that these
genes are differentially methylated in the brain. Although we were
able to validate many of the previously identified CpG sites,
experimental validation using an alternative method, such as
pyrosequencing, would also confirm our results. Functional
significance of genes found to be differentially methylated should
also be tested by gene expression.
Unsupervised clustering of the top 3000 most variable probes
revealed two distinct groups after adjusting for age and PMI.
Cluster 1 comprised 88% patients with schizophrenia and 12%
controls, whereas cluster 2 comprised 27% patients with schizo-
phrenia and 73% controls. To our knowledge, this is the first report
of DNA methylation profiling that is able to significantly
differentiate between those with schizophrenia and control
subjects. Although Nishioka et al.11 was able to identify site-
specific DNA methylation changes in patients with schizophrenia,
they were unable to discriminate between controls and schizo-
phrenia patients using unsupervised clustering.11 DNA methyla-
tion patterns differ in brain cells compared with peripheral tissues
such as blood,20 and this may explain the lack of separation
reported by Nishioka et al.11 Although some genes may have the
same epigenetic profiles in peripheral and brain tissue, a more
comprehensive list of tissue-specific genes may be required to
differentiate controls from those with schizophrenia. Another
reason may be the analysis of fewer CpG sites (only 27 000
compared with 450 000) in the previous study. This is potentially
important, as a DNA methylation signature across the whole
genome is required to identify the most important differentially
methylated probes. The results of our clustering analysis will need
to be confirmed in an independent brain tissue cohort.
Clustering analysis also revealed two subgroups within schizo-
phrenia. It is possible that these two subgroups have specific
symptomatology that warrants further investigation in a sample
set with a comprehensive clinical history. After adjusting for age
and PMI, DTNBP1, COMT and DRD2 were found to be differentially
methylated between the two schizophrenia subgroups. Interest-
ingly, these are genes that we have previously found to be
associated with schizophrenia.39–42
A recent study has found significant DNA methylation changes
in the early stages of development and suggest that aberrant DNA
methylation during the transition from the fetal to the postnatal
period of development could be critical for the pathogenesis of
schizophrenia.43 Genes that are differentially methylated from
fetal to neonatal life stage include DRD2, NOS1, SOX10 and DNMT1,
all of which have been previously found to be associated with
schizophrenia. We also found DNMT1, NOS1 and SOX10 to be
differentially methylated in brain tissue from patients with
schizophrenia. However, after adjusting for age and autolysis,
DRD2 was not differentially methylated.
The main limitation of our study was that patients were not free
of antipsychotic medication, and antipsychotic medication has
been shown to influence DNA methylation. A recent study
reported that antipsychotic haloperidol was uniquely associated
with higher global DNA methylation in patients with
schizophrenia, but other antipsychotic drugs were not associated
with changes in methylation.25 A further study observed that
antipsychotics may have anti-inflammatory effects.44 However, as
patients with chronic schizophrenia are almost certain to be
treated with antipsychotic medications, future studies may only be
able to adjust for antipsychotic medications in their analyses
rather than eliminate these samples entirely. Our samples were
obtained from a brain bank and had limited medication history
collected. Although controls did not have schizophrenia, they
were not screened for other psychiatric conditions such as
depression. Antipsychotic medication use was not screened for
among the control subjects, as these medications are not
commonly used other than to treat psychosis. Another limitation
is cell-type heterogeneity in the frontal cortex brain tissue used in
our analysis. Our study did not account for differences in cell type
seen in the frontal cortex, and a previous study has shown that the
two major cell types, neurons and glia, have different DNA
methylation signatures.45 Statistical methods that estimate brain
cell types in gene expression studies46 and, more recently, in DNA
methylation studies47 could be used in future brain DNA
methylation studies.
Our data indicate that studies of epigenetic changes in
schizophrenia hold promise for the future development of
diagnostic and prognostic biomarkers for schizophrenia, as well
as therapeutic options that target causative epigenetic alterations.
The key is to identify aberrant DNA methylation profiles in a
functional tissue and determine if the results can be translated
back into a diagnostically feasible tissue such as blood or saliva.
Identifying when DNA methylation changes occur is also
important in understanding the origins of schizophrenia. During
the critical period of development between pregnancy and birth,
altered DNA methylation occurs.43 If gene–environmental factors
that affect DNA methylation status can be identified, then the
incidence of schizophrenia could possibly be reduced by targeting
the environmental triggers. To put together all the pieces of the
schizophrenia puzzle, gene–environment interactions, as well as
how they influence epigenetics, need to be identified. Over the
years, there have been numerous studies on the effects of single-
nucleotide polymorphisms on mRNA expression in schizophrenia,
but very few showing how single-nucleotide polymorphisms
affect gene expression through DNA methylation. Investigating
the involvement of single-nucleotide polymorphisms and their
interaction with the environment, as well as their influence on
epigenetics, will benefit our understanding of the pathophysiol-
ogy of schizophrenia. The identification of enzymes that are
capable of mediating DNA demethylation in mammalian cells as
targets for therapeutic intervention is an exciting prospect that
may hold the key to reversing this debilitating psychiatric illness.48
CONFLICT OF INTEREST
The authors declare no conflict of interest.
Table 5. Number of probes found differentially methylated between schizophrenia subgroups
Unadjusted Adjusted Commona
Probes Genes Probes Genes
All 73 222 14 701 56 001 12 625 12 501
Promoter associated 6681 3979 4779 2934 2851
CpG island 10 628 4450 7598 3218 3106
Promoter associated and island 2006 1546 1238 919 861
aGenes in common with unadjusted results.
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